title: Evaluation of the Potency, Neutralizing Antibody Response, and Stability of a Recombinant Fusion Protein Vaccine for Streptococcus pyogenes.
abstract: Streptococcus pyogenes or group A streptococcus (GAS) is a Gram-positive bacterium that can cause a wide range of diseases, including pharyngitis, impetigo, scarlet fever, necrotizing fasciitis, rheumatic fever, and streptococcal toxic shock syndrome. Despite the increasing burden on global health caused by GAS, there is currently no licensed vaccine available. In this study, we evaluated immunogenicity, induction of neutralizing antibodies, and stability of a new recombinant fusion protein vaccine that targets infections from GAS. The recombinant fusion protein (SpeAB) combines inactive mutant forms of streptococcal pyrogenic exotoxin A (SpeA) and streptococcal pyrogenic exotoxin B (SpeB). The SpeAB vaccine evaluated in this study was adsorbed to an aluminum adjuvant and demonstrated robust immunogenicity, eliciting production of specific neutralizing antibodies against SpeA and SpeB, two major virulence factors of S. pyogenes. Stability studies suggest that the vaccine will retain immunogenicity for at least 2 years when stored at refrigerated temperatures. This novel vaccine shows great potential to provide protection against GAS infections and to reduce the burden of GAS disease globally.
authors.affiliation: VaxForm, LLC, Bethlehem, Pennsylvania, USA.
authors.forename: E
authors.initials: E
authors.lastname: Burlet
authors.affiliation: Department of Comparative Pathobiology, Purdue University, West Lafayette, Indiana, USA.
authors.forename: H
authors.initials: H
authors.lastname: HogenEsch
authors.affiliation: Department of Comparative Pathobiology, Purdue University, West Lafayette, Indiana, USA.
authors.forename: A
authors.initials: A
authors.lastname: Dunham
authors.affiliation: VaxForm, LLC, Bethlehem, Pennsylvania, USA. garry.morefield@vaxform.com.
authors.forename: G
authors.initials: G
authors.lastname: Morefield
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000096:biosynthesis; D005260:Female; D000071497:Immunogenicity, Vaccine; D008807:Mice, Inbred BALB C; D055550:Protein Stability; D011993:Recombinant Fusion Proteins; D013290:Streptococcal Infections / Q000517:prevention & control; D022541:Streptococcal Vaccines; D013297:Streptococcus pyogenes / Q000276:immunology*; D064166:Vaccine Potency
chemical_list: D057134:Antibodies, Neutralizing; D011993:Recombinant Fusion Proteins; D022541:Streptococcal Vaccines
keywords: Streptococcus pyogenes; vaccine formulation efficacy